<p>Pharmaceutical companies facing a steep patent cliff are concluding the key to future profits may be customized treatments tailored to patients' genes and lifestyles — not blockbusters aimed at large patient populations.Why it matters: The pivot could influence which diseases get treated in the deca</p>